Underscoring Critical Role of Science in a Smoke-Free Future, Philip Morris International Brings on Former Sanofi Exec as Chief Life Sciences Officer
Philip Morris International Inc. (PMI) (NYSE: PM) today announced the appointment of Jorge Insuasty to the position of Chief Life Sciences Officer, effective Jan. 15, 2021. Mr. Insuasty will report to the company’s CEO, André Calantzopoulos.
“Jorge’s wealth of experience across both the pharmaceutical and consumer healthcare industries makes him the ideal candidate to succeed John O’Mullane, who is retiring,” said Calantzopoulos. “Jorge is a transformational leader in science and medicine and excels in driving product portfolio development through to market success. Science and a consumer-focused product portfolio are the cornerstones of our ambition to replace cigarettes with products that are a better choice than continued smoking. Jorge’s impressive track record will help ensure we reach our goals and take full advantage of adjacent revenue-generating opportunities.”
Mr. Insuasty joins PMI from Sanofi S.A., where most recently he was the Global Franchise Head of Immunology, Oncology, and Neurology for Sanofi Genzyme. During his nine-year tenure at Sanofi he led the company’s product pipeline strategy, from candidate selection through the development and regulatory review processes, with a dozen novel drugs approved. He orchestrated significant transformational change within the R&D and commercial functions to substantially increase speed and efficiency, fostered external collaboration and innovation, and was highly engaged with the investor community. Overall, he played a pivotal role in the turnaround of Sanofi’s R&D efforts.
Prior to Sanofi, Mr. Insuasty spent eight years at Novartis International AG as Global Head of Development, Neuroscience, and Ophthalmology. Before that, he was VP, Research and Development, Consumer Medicines at Bristol Myers Squibb. Mr. Insuasty holds an MD in cardiology from the University of Paris.
“I am very excited to join PMI,” said Insuasty. “The company’s transformation, and smoke-free vision represent a tremendous public health opportunity and a business challenge, both of which I will be thrilled to contribute toward. And I also look forward to developing adjacent future growth drivers.”
This appointment follows the recent announcement that John O’Mullane, PMI’s current Chief Life Sciences Officer, will retire.
“We thank John for the enormous contributions he has made these last two years, driving innovation and rigor into our life sciences function, and we wish him well in his retirement,” added Calantzopoulos.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables to Altria Group, Inc. for sale under license in the U.S., where the U.S. Food and Drug Administration (FDA) has authorized their marketing as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of Sept. 30, 2020, PMI estimates that approximately 11.7 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 61 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com.
Philip Morris International
T. +41 (0)79 843 8603
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Velodyne Lidar Signs Multi-Year Sales Agreement with Emesent26.1.2021 13:00:00 CET | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced a multi-year sales agreement to provide Puck LITE™ sensors to Emesent, a world-leader in drone autonomy, lidar mapping and data analytics. Emesent is using Velodyne’s lidar sensors to power its award-winning Hovermap mobile scanning system for mapping hazardous and GPS-denied environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005229/en/ Emesent’s Hovermap, equipped with a Velodyne Puck LITE™ sensor, has a colorization feature for its 3D point clouds that brings additional context for visualization and analysis. (Photo: Emesent) Hovermap, which can be hand-held or mounted to a drone, uses Puck LITE lidar as its primary perception and mapping sensor. Equally capable above ground or underground, indoors or out, Hovermap combines advanced collision avoidance and autonomous flight technologies to map challenging, inaccessible areas. Hovermap has a coloriza
Allurion Technologies Launches Virtual Care Suite to Transform the Consumer and Provider Experience26.1.2021 13:00:00 CET | Press release
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fallurion.com%2F&esheet=52366910&newsitemid=20210126005074&lan=en-US&anchor=Allurion%26%23174%3B+Technologies&index=1&md5=a32a2cae6846c1f555e8ab3892c63eae Allurion® Technologies, a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced a major milestone for its AllurionTM Weight Loss Program with the launch of its new digital health offering featuring the Allurion TM Health Tracker smartwatch, Allurion® Connected Scale, Allurion® mobile app, and the Allurion TM Clinic Dashboard, the first in a series of new provider services that make up the Allurion TM Virtual Care Suite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005074/en/ The Allurion Connected Scale and Health Tracker measure all aspects of body composition including weight, body fat, muscle mass, as well as activity data such as steps, ex
Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index26.1.2021 12:35:00 CET | Press release
Takeda Pharmaceutical Company Limited(TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D capacity building, according to the Index. “This honor underscores Takeda’s commitment to prioritizing patient needs by ensuring access to our life-transforming treatments,” said Christophe Weber, Takeda president and chief executive officer. “As a purpose-driven company that puts the patient at the center of everything we do, we are committed to not just inventing medicines but making sure patients can access transformative therapies.” The AtM Index is a rigorous, biennial research project combining data-collection, verification, scoring and analysis
IFF Announces Preliminary Fourth Quarter & Full Year 2020 Financial Results26.1.2021 12:35:00 CET | Press release
IFF (NYSE:IFF), a leading innovator of taste, scent, and nutrition & ingredients, today announced preliminary, unaudited financial results for the quarter ended December 31, 2020. “In collaboration with DuPont’s financial announcement today, and in connection with the Exchange Offer related to our combination with DuPont Nutrition & Biosciences, we are providing preliminary financial results for the fourth quarter and full year 2020,” said IFF Chairman and CEO Andreas Fibig. “We expect to finish 2020 with results coming in ahead of our expectations despite continued challenges and complexity of the pandemic. This performance is a direct testament to the diversity of our portfolio, the essential nature of our products, and the resiliency of our global teams to continuously deliver for our customers.” Mr. Fibig continued, “With the completion of our merger with DuPont N&B now just days away, we continue to see multiple paths to strong value creation for all our stakeholders. Upon closing
Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in France26.1.2021 12:00:00 CET | Press release
Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France. Tilray will supply GMP-produced medical cannabis products to serve patients in need for the duration of the French experiment (18-24 months), due to begin in the first quarter of 2021. Tilray products will be administered to qualifying patients in the French experiment, for whom existing treatments do not provide sufficient relief from their symptoms, and for therapeutic indications including: Neuropathic pain that is refractory to therapies currently available (drug or non-drug treatments); Certain forms of epilepsy that are drug-resistant; In certain persistent symptoms in oncology, related to cancer or anti-cancer treatment; In palliative care s
Aqua Lung Welcomes World-Renowned Wildlife Photographer and Conservationist Paul Nicklen as a Global Ocean Ambassador26.1.2021 12:00:00 CET | Press release
Aqua Lung, the celebrated pioneer, designer, manufacturer and distributor of dive and watersports equipment for 75 years, today announced world-renowned wildlife photographer and conservationist Paul Nicklen is joining the brand as a global ocean ambassador. As part of the partnership, Nicklen will exclusively use Aqua Lung, Apeks, and O.ME.R. products during all dive expeditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005122/en/ Aqua Lung global ocean ambassador and SeaLegacy co-founder, Paul Nicklen with co-founder and President of SeaLegacy, Cristina Mittermeier. Photo credit: Joe Leahy Nicklen, best-known for his incomparable underwater photography and ocean conservation efforts, will utilize the full range of industry-leading Aqua Lung, Apeks and O.ME.R. products from wetsuits, masks and fins to technical gear and regulators. Helping to grow the brand globally, Nicklen joins an elite roster of ambassadors
New Study Concludes Xlear Kills and/or Deactivates SARS-CoV-2; Efficacy Against New Variants26.1.2021 10:15:00 CET | Press release
A new in vitro study done collaboratively by Utah State University and Northwestern University finds Xlear components (grapefruit seed extract and xylitol) significantly eliminates SARS-CoV-2, the virus that causes COVID-19. The imaging research study component was performed at the BioCryo facility of Northwestern University’s NUANCE Center. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005436/en/ Using electron microscopy, we have visual evidence showing that xylitol and grapefruit seed extract (GSE) counters the virus. The GSE kills the virus, while the xylitol prevents the virus from attaching to the cell walls. The image shows SARS-CoV-2 viruses outside the cell and never attached, thereby preventing infection (Photo: Business Wire) The study tested SARS-CoV-2 virus titers and LRV against a single concentration of Xlear nasal spray. According to the Study, “After a 25-minute contact time, the nasal spray reduced v